Skip to main content
SpringerLink
Log in

GDP more cost effective than DHAP for lymphoma

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2012 Canadian dollars

Reference

  • Cheung MC, et al. Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. Journal of the National Cancer Institute 107: No. 7, Jul 2015. Available from: URL: http://doi.org/10.1093/jnci/djv106

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

GDP more cost effective than DHAP for lymphoma. PharmacoEcon Outcomes News 726, 18 (2015). https://doi.org/10.1007/s40274-015-2066-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2066-1

Search

Navigation